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Abstract
Background: Some studies have suggested that breast cancer in black women is more aggressive than in white women. 
This study’s aim was to look for evidence of differences in tumour biology between the two cohorts.
Methods: This study compared the stage, grade and pathological expression of ﬁ  ve immunohistochemical markers (oestrogen 
receptor [ER], progesterone receptor [PR], ERBB2, P53 and cyclin D1 [CCND1]) in tumour biopsies from age-matched 
cohorts of patients from Nigeria and England. Sixty-eight suitable samples from Nigerian (n = 34) and British (n = 34) 
breast cancer patients were retrieved from histology tissue banks.
Results: There were signiﬁ  cant differences between the two cohorts in the expression of ER and CCND1; and stark differences 
in the clinical stage at presentation. But no signiﬁ  cant differences were observed for tumour grade.
Conclusion: There was a signiﬁ  cantly, low ER expression in the Nigerian cases which also predicts a poor response to 
hormonal therapy as well as a poorer prognosis. Differences in clinical stage at presentation will most likely inﬂ  uence 
prognosis between Nigerian and British women with breast cancer.
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Introduction
There is signiﬁ  cant worldwide variation in the incidence and mortality from breast cancer. (Key et al. 
2001) Studies carried out in the United States among white and black women have found that black 
women have a lower lifetime risk of breast cancer but have poorer survival rates following diagnosis. 
(Harris et al. 1992; Elledge et al. 1994) The same trends can be seen between Nigerian and English 
populations in the reported incidence of symptomatic breast cancer and subsequent ﬁ  ve year survival. 
(Ihekwaba, 1992; Ihezue CH et al. 1994; Quinn M and Allen E, 1995; Okobia and Osime, 2001)
Many factors could explain differences in reported disease incidence and mortality. Demographic 
variation such as life expectancy will affect breast cancer incidence rates (Gukas ID et al. 2006) 
and socioeconomic differences affect awareness of breast cancer, access to healthcare (including 
screening) and reporting rates through cancer registries. (Harris et al. 1992; Ihekwaba, 1992; Gwyn 
et al. 2004)
However, environmental and/or genetic factors could lead to differences in tumour biology; such 
differences may result in differential response to treatment. Elledge et al. showed that black Americans 
were less likely to have tumours with positive ER and PR status (Elledge et al. 1994) and had poorer 
survival than white Americans.
In this study we have compared the tumour type, grade, disease stage and the expression of a panel of 
immunocytochemical markers in age-matched cohorts of breast cancer patients from Nigeria, a predominantly 
black population (over 99.9%) (National Population Commission of Nigeria. 1998), and England, within a 
predominantly white population (over 97% in Liverpool and 98% in East Anglia) (U.K. National Statistics,). 348
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Our aim was to look for evidence of differences in 
tumour biology between the two cohorts.
Methods
Ethics and research governance
This study had approval from the ethics committee 
of Jos University Hospital, Plateau State, Nigeria 
and from the custodians of the Royal Liverpool 
and Broadgreen University tissue bank; the 
Norfolk and Norwich University Hospital 
research governance and local research ethics 
committees have also approved this study (LREC 
2002-3/049).
Histology and TNM staging
46 Parafﬁ  n-wax embedded tissue biopsies were 
retrieved from the histopathology archives of Jos 
University Teaching Hospital, Nigeria; these were 
from a consecutive series of breast cancer patients 
diagnosed between 1999 and 2001. Analysis of 
haematoxylin and eosin stained sections from these 
blocks was used to determine if there was adequate 
tumour material available for subsequent tumour 
grading and immunocytochemistry. 34 cases were 
considered suitable. The clinical staging informa-
tion, using the tumour node metastasis (TNM) 
system, was obtained for these cases based on 
physical examination and palpation. Pathological 
staging is not routinely carried out in Nigeria 
because of limited healthcare resources.
The 34 Nigerian cases were paired with age-
matched British breast cancer cases held at tissue 
banks in Norwich (n = 14) and Liverpool (n = 20). 
Paraffin wax embedded tissue biopsies were 
retrieved for these cases along with pathological 
staging data, using the TNM system.
The 68 tumours were typed and graded 
histologically according to national guidelines. 
(Royal College of Pathologists, 2005)
Immunocytochemistry
Immunocytochemical staining of tissue sections 
from parafﬁ  n wax embedded biopsies was per-
formed within the diagnostic laboratories of the 
histopathology department at Addenbrooke’s hos-
pital, Cambridge. Antigen retrieval was achieved 
by microwave oven incubation for ﬁ  ve minutes in 
citrated buffer (0.01M: pH 6.0) testing for ER, 
PGR, ERBB2 and p53 oncoproteins and in 1mM 
EDTA (pH 8.0) for CCND1. Antigen localisation 
was achieved by incubating sections with primary 
antibodies at various dilutions.
Sections were incubated with the antibodies 
ERBB2 (Dako, Glostrup, Denmark) at a dilution 
of 1:1000, ER (6F11; Novacastra, Newcastle, U.K.) 
at a dilution of 1:15, PGR (PgR 636; Carpinteria, 
U.S.A.) at a dilution of 1:50, P53 (DO-7; DAKO 
Glostrup, Denmark) at a dilution of 1:50 and 
CCND1 (P2D11F11; Novacastra, Newcastle, U.K.) 
at a dilution of 1:20. The indirect avidin-biotin 
complex (ABC) procedure was applied for detection 
of the bound antibody. Scoring was carried out by 
two independent scorers (IG and AG). Nuclear 
staining of at least 10% of malignant cells was 
considered positive for ER, PR, Cyclin D1 and P53. 
Cell membrane staining of at least 5% was used as 
a cut off for ERBB2 positive staining.
Statistics
The Chi square or Fisher’s exact test with Yate’s 
correction was used to compare the data from the 
two cohorts.
Results
Histology and TNM staging
The mean age of the cohort of 68 patients was 45 
(median age 43 years, and age range 26–81 years).
Analysis of tumour type showed that 33 of the 
Nigerian cases were invasive ductal carcinomas of 
no special type (NST). One tumour was poorly 
differentiated and showed spindle cell/sarcomatoid 
features. There were no carcinomas of invasive 
lobular type. In the British cohort, 31 cases were 
invasive ductal carcinomas NST. There were two 
cases of mixed type (showing both ductal and 
lobular features) and one medullary carcinoma.
The tumour types and grades of these 68 tumour 
are shown in tables 1 and 2. Ten high power ﬁ  elds 
were examined to grade the tumour. For two of the 
(grade 2) Nigerian cases, the amount of tumour 
present was small and there was extensive necrosis, 
precluding the analysis of 10 high power ﬁ  elds; 
therefore these two cases may have been under-
scored for mitoses and thus grade. There were no 
signiﬁ  cant differences in the grades of the age 
matched tumour in the two cohorts, regardless of 
the scoring (as grade 2 or 3) of the two Nigerian 
cases discussed above.349
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There were differences in the TNM staging data 
for the two cohorts (see Table 1) 61.8% of the Nige-
rian tumours being TNM stage 3 or 4 compared with 
11.8% of the British tumour.
Immunocytochemistry
The number of cases showing expression of ER 
and CCND1 was signiﬁ  cantly higher in the British 
cohort than in the Nigerian cohort. Other markers 
showed no signiﬁ  cant differences. The results of 
the statistical analyses for these 68 cases are shown 
in Table 2.
We have also compared the expression of the 
different molecular markers seen in clinical stages 
1&2 (early stage) and clinical stages 3&4 (late 
stage) between U.K. cases and the Nigeria cases, 
as shown in Table 3. Only ER expression showed 
signiﬁ  cant difference.
Discussion
In this study we compared the histological and 
immunocytochemical profiles of age-matched 
cohorts of Nigerian and British breast cancer cases. 
The average age of the cohort of 68 cases was 
determined by the cases selected in Nigeria and was 
young (mean age = 45.2) relative to a typical series 
of British cases. (Gukas ID et al. 2006) The 
incidence of special type carcinomas was also low 
relative to other series. (Simpson and Page, 1994)
There were no signiﬁ  cant differences between the 
cohorts for tumour grade. Immunocytochemical 
studies showed no signiﬁ  cant differences between 
the cohorts in the cases expressing the poor 
prognostic markers P53 and ERBB2. The number 
of cases positive for ER and CCND1 was signiﬁ  cantly 
higher in the cohort of British cases. A large study 
by Elledge et al. showed that breast tumours are more 
likely to be ER negative in black than white 
Americans but showed no differences in the 
expression of P53 or ERBB2. (Elledge et al. 1994)
An inverse relationship between ER and PR 
expression and high tumour grade has been 
previously documented (Millis, 1980) and was 
also noted for the Nigerian tumours (p = 0.006 for 
ER and p = 0.002 for PR) but there was a less 
signiﬁ  cant trend for the British tumours (p = 0.053 
for ER and p = 0.014 for PR). It has been suggested 
that, as part of the natural history of breast cancer, 
some tumours tend to lose hormone receptor status 
by progressive genetic alterations (Stoner et al. 
2002). The difference in receptor status between 
the two groups could therefore be explained by 
the late stage of the Nigerian cases. This is 
supported by our ﬁ  nding of consistent lack of 
Table 1. The histological types and staging data for 68 British and Nigerian tumors.
Invasive ductal NST Other TNM stage 1 TNM stage 2 TNM stage 3 TNM stage 4
Nigerian tumor
(n = 34)
33 1* 0
(0%)
13
(38.2%)
14
(41.2%)
7
(20.6%)
UK tumor
(n = 34)
31 3
† 5
(14.7%)
25
(73.5%)
4
(11.8%)
0
(0%)
The cases were staged using the UICC TNM system; preoperative clinical staging is shown for the Nigerian cohort; pathological staging 
was used for the British cohort.
*Poorly differentiated carcinomas with sarcomatoid features.
†Two cases were of mixed type (showing both ductal and lobular features) and one case was a medullary carcinoma.
Table 2. The immunocytochemical and grading data 
for 68 British and Nigerian tumor.
UK samples
positive/total 
(%)
Nigerian 
samples
positive/total 
(%)
p value
Molecular 
markers
ER 20/34 (58.8) 9/34 (26.5) p = 0.0142
PR 18/34 (52.9) 10/34 (29.4) p = 0.0846
ERBB2 15/34 (44.1) 8/34 (23.5) p = 0.1241
CCND1 9/33 (27.3) 2/33 (6.1) p = 0.0475
P53 13/34 (38.2) 17/34 (50) p = 0.4637
Histological 
Grade
Grade 1 1/34 (2.9) 2/34 (5) p = 1 
(Fisher’s 
exact)
Grade 2 12/34 (35.3) 8/34 (23.5) p = 0.4246
Grade 3 21/34 (61.8) 24/34 (70.6) p = 0.6082
The result of grading and immunohistochemistry for ER, PR, ERBB2, 
P53 and CCND1 for the age-matched samples. There were signiﬁ  cant 
differences for ER and CCND1 expression only (p   0.05).350
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expression of ER in the Nigerian tumours when 
early and late stage tumours were compared in the 
two countries (p = 0.0477 and p = 0.0261 
respectively). The Nigerian tumours were close 
to the upper size limit for each stage. Our ﬁ  nding 
that tumour grade remained the same for both 
populations whereas stage and hormone status 
were worse for the Nigerians may support the 
notion that tumour grade does not deteriorate 
longitudinally. (Millis et al. 1998)
Other studies have shown that tumours that 
express hormone receptors are also more likely 
to express CCND1 (Shoker et al. 2001). This 
correlation was also seen for the British tumours 
(p = 0.004 for ER and p = 0.001 for PR) but there 
was no signiﬁ  cant correlation for the Nigerian 
tumours (p = 0.068 for ER and p = 0.085 
for PR).
21 of the 34 Nigerian cases presented with TNM 
stages 3 and 4. Pre-operative clinical staging was 
used for these cases which may incorrectly stage 
the tumour when compared with the gold standard 
of pathological staging. (Bosch et al. 2003) How-
ever, our data concur with other studies of Nigerian 
cohorts showing that patients commonly present 
with very large primary breast tumour and matted 
palpable axillary nodes and consequent high TNM 
stage. (Ihekwaba, 1992; Ihezue CH et al. 1994; 
Okobia and Osime, 2001) The risk of over-staging is 
low when tumours are close to the upper size limit 
for a particular stage. (Benson et al. 2003) Therefore, 
despite the limitation described with the use of dif-
ferent staging methods, we are conﬁ  dent that there 
are clear differences in TNM staging between the 
two cohorts; stages 3 and 4 being more common 
for the Nigerian than the British cases (odds 
ratio = 12.1, conﬁ  dence interval = 3.5 to 42.4).
Conclusions
There were signiﬁ  cant differences in hormone 
receptor levels. This will predict poorer response 
to hormonal therapy and overall poorer prognosis 
in the Nigerian patients compared to the British 
patients. The difference observed in the frequency 
of CCND1 expression is an interesting ﬁ  nding, 
warranting further investigation. The late stage at 
presentation in the Nigerian cases could partly 
explain the difference in breast cancer prognosis 
for Nigerian and British women. There is a need 
for a stage for stage comparison to further study 
this subset of tumours.
These conclusions should now be tested in a 
large prospective case—controlled study.
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